If you’ve spent any time on health news this past week, you’ve probably seen the headlines: a massive new study suggests that GLP-1 medications — the drug class that includes Ozempic, Wegovy, Mounjaro, and Zepbound — may do more than help with blood sugar and weight. Researchers in Finland, Sweden, and Australia tracked nearly 100,000 patients and found that people taking semaglutide had measurably lower rates of depression, anxiety, and substance-use issues during their treatment periods.

It’s a striking finding, and patients have been bringing it up at our pharmacy counters this week. So let’s walk through what the study actually found, what it doesn’t tell us, and how I’d think about it as a pharmacist.

What the New Study Actually Found

The research, published in The Lancet Psychiatry in late April 2026, was led by investigators at the University of Eastern Finland, the Karolinska Institutet in Stockholm, and Griffith University in Australia. It pulled from national health registers covering close to 100,000 adults followed for more than a decade.

The headline numbers, as reported by ScienceDaily and Newsweek:

• Risk of depression was about 44% lower during semaglutide use compared to periods off the medication.
• Risk of anxiety disorders was about 38% lower.
• Hospital visits and sick leave for psychiatric reasons were roughly 42% lower.
• Substance-use-related hospital care and sick leave were about 47% lower.
• Suicidal behavior was less frequent during treatment windows.

Those are big effect sizes, and they’re consistent with several smaller studies that have hinted at the same pattern over the past two years.

Why Researchers Think This Might Be Happening

GLP-1 receptors aren’t only found in the pancreas and gut — they’re also expressed in parts of the brain involved in reward, mood, appetite, and impulse control. Animal studies have shown that GLP-1 signaling in the brain can blunt reward responses to food, alcohol, and nicotine. That’s the leading hypothesis for why these medications appear to reduce cravings well beyond just hunger.

The other possibility is more straightforward: losing significant weight, getting blood sugar under control, sleeping better, and feeling more in command of one’s eating can all improve mood on their own. Most patients in the study were taking semaglutide for type 2 diabetes or obesity, both of which independently raise the risk of depression. Treating the underlying condition may simply lift some of the mental health burden that came with it.

The honest answer is that we don’t yet know how much of the benefit is direct (a brain effect from the drug) versus indirect (better metabolic health, better sleep, weight loss). Both are likely contributing.

What This Study Doesn’t Prove

This is where the conservative pharmacist hat goes on. A few important caveats:

First, this is an observational study, not a randomized trial. Researchers compared the same patients during periods on and off the medication, which is a strong design — but it can’t fully rule out that people who stay on GLP-1s long-term differ in ways that also affect mental health (more engagement with their doctor, better follow-up, healthier overall).

Second, not every GLP-1 study has been positive. A 2024 paper in Scientific Reports found no significant change in depression risk, and earlier this year researchers at Medscape highlighted a separate Swedish cohort showing more nuanced results in patients who already had a psychiatric diagnosis. Some patients on GLP-1s — particularly those with a prior history of severe depression — have reported worsening mood, and the FDA continues to monitor reports of suicidal ideation associated with this drug class.

Third, this study looked at semaglutide specifically. We can’t assume the same effect applies equally to tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda), or the next-generation agents in development.

And fourth — the most important point — nothing in this study suggests GLP-1 medications should be prescribed to treat depression or anxiety. They are not approved for that purpose, and we have effective, well-studied medications for mental health conditions that don’t require weekly injections, prior authorizations, or compounded shortages.

A Pharmacist’s Perspective

Here’s what I’d tell you across the counter at our Statesboro store, or in Brooklet or Lyons: this is encouraging research, not a green light. If you’re already on a GLP-1 for diabetes or weight management and you’ve noticed your mood is steadier, that tracks with what the data is showing — and that’s a real benefit worth holding onto.

If you’re considering a GLP-1 medication, the conversation with your prescriber should still center on what these drugs are actually approved for: type 2 diabetes, cardiovascular risk reduction in certain patients, and chronic weight management. Mental health benefits, if they materialize for you, are a bonus, not the goal.

If you have a history of depression, anxiety, eating disorders, or substance use, mention it before starting a GLP-1. The picture in patients with pre-existing psychiatric conditions is genuinely mixed, and your prescriber needs that history to make a good decision with you.

And if you’re already on a GLP-1 and you notice your mood getting worse — more anxious, more depressed, more impulsive — please tell your doctor or pharmacist right away. Don’t wait it out. We see people every week on these medications, and we’d rather hear about a concern early.

Frequently Asked Questions

Can I get a GLP-1 prescription for depression or anxiety?

No. GLP-1 medications are not FDA-approved for depression, anxiety, or any psychiatric condition. They are approved for type 2 diabetes and chronic weight management. Any mental health benefit observed in this study was secondary to their primary indication.

Should I stop taking my antidepressant if I start a GLP-1?

Absolutely not, and not without talking to your prescriber. This study does not show that GLP-1s replace antidepressants. Stopping a psychiatric medication abruptly can cause withdrawal symptoms and a return of underlying conditions.

Are these benefits seen with all GLP-1 drugs, or just Ozempic and Wegovy?

The published study focused on semaglutide, the active ingredient in Ozempic and Wegovy. Tirzepatide, liraglutide, and other agents in this class may behave similarly, but we don’t have the same large-scale mental health data on them yet.

I live near Statesboro — can Walker Pharmacy help me manage a GLP-1 prescription?

Yes. We dispense GLP-1 medications at all four Walker Pharmacy locations across Bulloch and Toombs Counties, and we counsel patients on injection technique, side effects, storage, and what to do during a missed dose. If you’re navigating supply issues or insurance prior authorizations, our team handles those calls every day.

Where can I read the original study?

The full paper is available in The Lancet Psychiatry (April 2026). News summaries from ScienceDaily, Newsweek, and Global News covered the findings the week of publication.

Talk to a Pharmacist Who Knows You

One of the things I love about running an independent pharmacy in Southeast Georgia is that we actually know our patients. If you’re starting a GLP-1, switching from one to another, or just trying to make sense of the headlines, come talk to us. Walking through new research is part of the job, and we’d rather have that conversation in person than have you guess.

If you’d like to move your prescriptions to a pharmacy that picks up the phone and remembers your name, you can transfer your prescriptions to Walker Pharmacy here. It takes about two minutes.

This article is for informational purposes only and does not constitute medical or health advice. Always consult your physician or pharmacist before making changes to your health regimen.

— Jordan Walker, PharmD | Owner, Walker Pharmacy